The UK's NHS is under pressure to meet the growing and changing demand for services with limited resources. Innovations may provide opportunities to respond creatively and effectively to growing health demands.
A review of the research needs and expenditure on pregnancy in the UK found that £51 million is invested in pregnancy research each year. By contrast, the NHS spends £5.8 billion on pregnancy-related care each year and in 2018/19 litigation claims totalled £2.5 billion.
Investing in malaria vaccination for children in sub-Saharan Africa not only helps in reducing malaria cases and deaths, it could also have long term macroeconomic benefits according to an economic model researchers developed.
MS is associated with high economic costs to society that go beyond the costs to the healthcare system, but researchers found limited evidence on the impact of disease progression on patients, carers, and society as a whole.
Significant barriers exist to creating enduring change in physical activity, but societies would be healthier and global GDP could increase as much as $760 billion by 2050 if everyone increased their physical activity.
In the EU, 26 million children under age 15 are exposed to household damp, noise, darkness and cold, which is associated with poorer health outcomes. Eliminating children’s exposure to household damp and mould could save $62 billion over the next 40 years.
The EMA fee system is generally efficient and effective, but it is not cost-based at a granular level and not always flexible, and over time it has become increasingly complex. Additionally the EMA relies on both industry fees and EU and EEA budget contributions to meet the costs of all its activities.
Research on different health and social care funding models assessed the popularity of different funding approaches among the UK public. Previous research examined other countries' funding schemes and found there is no single, commonly preferred solution to achieving sustainable revenues.
The UK makes an important contribution to public health research, as measured by citations in National Institute for Health and Care Excellence public health guidelines. However, the extent to which public health guidelines reflect practice at the local authority level is less clear.
The Vitality Age Calculator is an online tool that gives users a ‘snapshot’ of their overall health based on lifestyle choices and clinical factors. RAND Europe helped to update the calculator's methodology and use of available data.
Treating breast cancer early does not prevent its recurrence, but doing so can have implications for future research, policy, and practice. Researchers explored the evidence base on the broader health, societal and economic impacts from early breast cancer treatment and the wider costs to society of the progression of breast cancer.
RAND Europe and partners measured the use of ICT and eHealth applications by primary care physicians in the EU 28 Member States and Norway, compared the results with a 2013 study, and analysed the main drivers of change and factors that can enhance or inhibit the role and use of technologies within health care.
Researchers explored how to improve the evaluation and evaluability of services for older people in the UK and made several recommendations for different stakeholder groups, including commissioners, evaluators, service providers, and national policymakers in NGOs and government.
Researchers assessed changes in hospital utilisation following implementation of case management interventions in two boroughs of south London, in comparison to similar populations elsewhere. They found that the additional investment made through the programme cost more than it saved, possibly through the identification of unmet need.
Researchers assessed a new approach to paying for cancer drugs in England’s National Health Service based on achieved outcomes. Their findings may help to improve patient access to medicines and ensure value for the NHS.
To ensure the continued excellence of the UK’s research and innovation (R&I) base, the existence and continuity of funding is key. Additionally, numerous interacting conditions are needed to translate research and stimulate innovation, but there is no ‘magic formula’ for these conditions to be implemented.
Economic analyses offer a compelling case for the benefits that research and innovation (R&I) can deliver, but R&I also offers numerous benefits that are either not easily monetised or not well understood. These include benefits to culture, public engagement, social cohesion and the environment.
Dance4life, an international youth initiative to raise awareness and promote prevention of HIV/AIDS, developed and piloted a new programme and implementation model. An evaluation of the pilot found many successes but also areas where improvements could be made.
Because of its growth, the UK charity Tommy’s is developing a new strategy for their spending on efforts to reduce stillbirth, preterm birth, and miscarriages. Researchers examined the metrics Tommy's currently uses and suggested additional metrics to measure the impact of the charity's work.
RAND Europe and the University of Cambridge tested whether the Q Improvement Lab approach could become an effective, valuable way of developing ideas or interventions to support positive change at multiple levels of the health and care system.
Stakeholders and 'customers' say the Eastern Academic Health Science Network's TSU—which helps implement innovative solutions to challenges faced by health and care providers—has supported them with their pilots and network building. An evaluation provides recommendations for further improvements.
Many health and wellbeing interventions are available to UK employers. Researchers graded them against Nesta standards and developed case studies of the most promising practices that support policy and organisational decision making.
Health and social care services in five SIB-funded projects were more flexibly provided than in similar non-SIB projects, but it is unclear whether this resulted in better client outcomes. Attribution of outcomes to the SIB-financed intervention should be prioritised in the future.
The Canadian Institutes of Health Research asked RAND Europe to update the 2009 study on grant peer review to provide a more widely applicable source of evidence around the strengths and weaknesses of peer review for grant funding assessment.
A team of researchers from RAND Europe, King’s College London and HERG estimated the health and economic benefits of UK investment in medical research into musculoskeletal disease (MSD). Their best estimate of the internal rate of return from MSD-related research was 7%, which is similar to the 9% for cardiovascular disease and 10% for cancer research.